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Age+of+infant+ Vaccine+ Route+ Previous+ 2009+
Schedule+
At+birth+ BCG!! ID! √! √!
OPV! PO! √! √!
6+weeks+ OPV!! PO! √! √!
RV! PO! ! √!
DTP/Hib!! IM! √! !
DTaPDIPV/Hib!! IM! ! √!
HBV! IM! √! √!
PCV7! IM! ! √!
10+weeks+ OPV! PO! √! !
DTP/Hib! IM! √! !
DTaPDIPV/Hib! IM! ! √!
HBV! IM! √! √!
14+weeks+ OPV! PO! √! !
RV! PO! ! √!
DTP/Hib! IM! √! !
DTaPDIPV/Hib! IM! ! √!
HBV! IM! √! √!
PCV7! IM! ! √!
9+months+ Measles!! IM! √! √!





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Median!age!in!years!(IQR)! 27.5!(24!–!31.25)! 24!(20D27.25)! .001!
Normal!vaginal!delivery! 46!(100%)! 62!(100%)! 1.00!
Primigravidity! 12!(26%)! 30!(48%)! .02!
BMI!at!delivery! 28.10!(25.55!D!31.69)! 27.28!(24.10!D!33.97)! .95!


























!! HIVDexposed,!uninfected!infants! HIVD!unexposed!infants! p!value!
Gestation,!weeks! 38+3!(37+1!D!39+6)! 38+4!(35+1!D!40+1)! .36!
Female! 26!(57%)! 34!(55%)! 1.00!
Birth!weight,!kg! 3.13!(2.90!D!3.45)! 3.12!(2.98!D!3.47)! .59!
Weight!at!6!weeks,!kg! 4.60!(4.20D!5.19)! 4.77!(4.49!D!5.18)! .15!
Weight!at!16!weeks,!kg! 6.39!(6.02!D!6.98)! 6.73!(6.25!D!7.40)! .16!
HC!at!birth,!cm! 34!(33!D!35.6)! 34!(33D35)! .35!
HC!at!6!weeks,!cm! 38!(37D40)! 38.3!(37.1!D!39.3)! .56!
HC!at!16!weeks,!cm! 42!(41!D!43)! 42!(41!D!43)! .98!
Length!at!6!weeks,!cm! 54!(51.9!D!56.1)! 54.3(53!D!55.9)! .51!
Length!at!16!weeks,!cm! 60.5!(58.9!D!63)! 61.5(60!D!63)! .18!
Breast!fed!at!birth! 0!(0%)! 62!(100%)! <.!001!
Breast!fed!at!6!weeks! 0!(0%)! 51!(90%)! <!.001!













































Negative! 28! 9! 37!
Positive! 15! 44! 59!


























Negative! Positive! Negative! Positive!
TST!
Negative! 15! 7! 22!
TST!
Negative! 13! 2! 15!
Positive! 3! 13! 16! Positive! 12! 31! 43!
































































































Informal!housing!structure!! 79! 55! .01!
Running!water!in!house!! 32! 55! .02!
Flush!toilet!in!house!! 29! 52! .03!
Cell!phone! 95! 89! .47!
Landline! 0! 2! 1!
Electricity! 87! 89! .75!
Fridge! 73! 63! .29!
DVD!player! 70! 57! .2!
Television! 87! 75! .18!
Radio! 65! 59! .67!
Car! 14! 11! .75!
Bicycle! 5! 5! 1.00!
Completed!secondary!school!! 92! 93! 1.00!
Mother!in!regular!employment! 21! 23! 1.00!




































































































































































































































1.61! 0! 0! 0! 1.32! 0! 0!
CD8+ 0!
!
8.00! 9.01! 0! 0! 0.07! 7.57!
ILS17+ 0! 0.33!
!
17.79! 0! 0! 0! 0.97!
IFNSγ + 0.07! 4.64! 2.26!
!
0.09! 0! 0.05! 7.62!
Live/Dead+ 0.12! 0.12! 0! 0!
!
1.68! 0.10! 0!
CD3+ 0! 0! 0! 0! 0!
!
0.61! 0!
Ki67+ 0.41! 5.84! 0! 0! 0! 12.87!
!
0.82!
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!! !! !! CD8DKi67+!
Group!! Time!point! n! IFNDγ+! TNFDα+! ILD2+! ILD17+!
HIVD!QFN!D! Birth!
7!(4)!
0.08!(0.06)! 0.18!(0.21)! 0.49!(0.86)! 0.82!(2.68)!
HIVD!QFN!D! 16!weeks! 24.1!(3.93)! 22.75!(2.94)! 14.78!(1.65)! 8.02!(6.67)!
HIVD!QFN!+! Birth!
16(13)!
0.29!(0.27)! 0.66!(0.57)! 0.48!(0.48)! 0.09!(0.84)!
HIVD!QFN!+! 16!weeks! 21.12!(4.76)! 20.93!(4.75)! 13.27!(2.56)! 3.47!(1.31)!
HIV+!QFN!D! Birth!
4!(3)!
0.16!(0.16)! 0.5!(0.36)! 0.39!(0.5)! 0.05!(0.15)!
HIV+!QFN!D! 16!weeks! 30.54!(0.24)! 33.71!(0.35)! 13.7!(1.1)! 8.46!(4.03)!
HIV+!QFN!+! Birth!
5!(5)!
1.36!(0.48)! 3.03!(0.88)! 1.24!(0.88)! 0.03!(0.05)!
HIV+!QFN!+! 16!weeks! 22.88!(9.72)! 22.75!(7.5)! 14.69!(6.59)! 2.73!(2.59)!
Total!(Birth)! ! 32(25)! 0.32!(0.3)! 0.74!(0.64)! 0.57!(0.58)! 0.13!(0.84)!Total!(16!weeks)! 23.14!(4.43)! 23.06!(4.03)! 13.87!(2.52)! 4.42!(2.5)!
Effect!of!time! p! <!.0005! <!.0005! <!.0005! <!.0005!
Effect!of!time!and!maternal!















!! !! !! CD8+Ki67+!
Group! Time!point! n! IFNDγ+! TNFDα+! ILD2+! ILD17+!
HIVD!QFN!D! Birth!
7!(4)!
0.09!(0.06)! 0.1!(0.17)! 0.22!(0.11)! 0.1!(0.28)!
HIVD!QFN!D! 16!weeks! 5.24!(3.32)! 2.42!(1.62)! 0.79!(0.57)! 0.32!(0.19)!
HIVD!QFN!+! Birth!
16(13)!
0.32!(0.47)! 0.39!(0.45)! 0.43!(0.4)! 0.12!(0.81)!
HIVD!QFN!+! 16!weeks! 4.66!(0.86)! 3.74!(0.82)! 2.34!(0.67)! 2!(2.28)!
HIV+!QFN!D! Birth!
4!(3)!
0.29!(0.04)! 0.22!(0.1)! 0.14!(0.08)! 0.02!(0.02)!
HIV+!QFN!D! 16!weeks! 10.17!(1.56)! 8.14!(0.7)! 2.69!(0.37)! 4.94!(10.71)!
HIV+!QFN!+! Birth!
5!(5)!
1.31!(1.33)! 1.72!(1.01)! 0.17!(0.41)! 0.1!(0.07)!
HIV+!QFN!+! 16!weeks! 5.3!(1.14)! 4.88!(0.93)! 2.17!(0.64)! 2.09!(1.44)!
Total!(birth)! ! 32(25)! 0.35!(0.49)! 0.41!(0.49)! 0.29!(0.29)! 0.1!(0.46)!Total!(16!weeks)! 5.47!(1.46)! 4.04!(1.05)! 1.94!(0.63)! 1.91!(2.5)!
Effect!of!time! p! <!.0005! <!.0005! <!.0005! 0.003!
Effect!of!time!and!maternal!




































































































IFNSγ++ ILS2++ TNFS+α+++ ILS17++ IFNSγ++ ILS2++ TNFS+α+++ ILS17++
Overall+cohort+(n=49)+ rs! 0.14! 0.45! 0.22! D0.17! 0.27! 0.49! 0.39! 0.23!
+
p! 0.36! 0.001+ 0.13! 0.29! 0.07! <+.0005+ 0.006+ 0.15!
HIVS+(n=32)+ rs! 0.37! 0.50! 0.12! D0.03! 0.29! 0.53! 0.43! 0.28!
+
p! 0.04! 0.004+ 0.66! 0.88! 0.11! 0.002+ 0.02+ 0.16!
HIV++(n=17)+ rs! D0.18! 0.29! 0.30! D0.42! 0.25! 0.37! 0.30! 0.06!
+
p! 0.49! 0.26! 0.09! 0.16! 0.33! 0.14! 0.24! 0.85!
QFN+S+(n=22)+ rs! D0.24! 0.44! D0.24! D0.32! D0.05! 0.45! 0.02! D0.14!
+
p! 0.28! 0.04+ 0.28! 0.23! 0.84! 0.03+ 0.93! 0.60!
QFN++(n=26)+ rs! 0.36! 0.50! 0.47! D0.10! 0.32! 0.49! 0.52! 0.48!
+
p! 0.07! 0.01+ 0.02+ 0.65! 0.11! 0.01+ 0.007+ 0.02+
HIVS+QFNS+(n=14)+ rs! 0.02! 0.58! D0.12! D0.22! D0.05! 0.56! 0.20! D0.08!
+
p! 0.94! 0.03+ 0.70! 0.54! 0.88! 0.04+ 0.49! 0.82!
HIVS+QFN++(n=18)+ rs! 0.59! 0.44! 0.55! 0.09! 0.44! 0.49! 0.56! 0.52!
+
p! 0.01+ 0.06! 0.02+ 0.74! 0.07! 0.04+ 0.02+ 0.31!
HIV++QFNS+(n=8)+ rs! D0.40! 0.00! D0.51! D0.48! D0.10! 0.17! D0.12! D0.22!
+
p! 0.33! 1.00! 0.20! 0.33! 0.81! 0.70! 0.78! 0.68!
HIV++QFN++(n=8)+ rs! 0.19! 0.63! 0.04! D0.70! D0.23! D0.17! D0.10! 0.25!





























! ! ! ! ! ! ! ! !
Group+ ++
CD8+Ki67++ CD8SKi67++
IFNSγ++ ILS2++ TNFS+α+++ ILS17++ IFNSγ++ ILS2++ TNFS+α+++ ILS17++
Overall+cohort+(n=63)+ rs! 0.02! 0.32! 0.10! 0.23! D0.11! 0.03! D0.01! D0.05!
+ p! 0.88! 0.01+ 0.46! 0.09! 0.39! 0.83! 0.93! 0.74!
HIVS+(n=32)+ rs! D0.1! 0.27! 0.06! 0.27! D0.18! D0.02! D0.11! 0.09!
+ p! 0.57! 0.12! 0.73! 0.17! 0.29! 0.92! 0.55! 0.64!
HIV++(n=17)+ rs! 0.15! 0.36! 0.18! 0.17! 0.00! 0.008! 0.13! D0.26!
+ p! 0.46! 0.06! 0.37! 0.39! 1.00! 0.97! 0.53! 0.19!
QFN+S+(n=22)+ rs! 0.16! 0.18! 0.06! 0.12! D0.16! 0.02! D0.01! D0.21!
+ p! 0.44! 0.39! 0.79! 0.61! 0.44! 0.94! 0.95! 0.36!
QFN++(n=26)+ rs! D0.08! 0.35! 0.13! 0.31! 0.01! 0.03! 0.003! D0.01!
+ p! 0.65! 0.04+ 0.45! 0.09! 0.95! 0.89! 0.99! 0.97!
HIVS+QFNS+(n=12)+ rs! D0.14! 0.22! D0.31! 0.21! D0.47! D0.17! D0.43! D0.30!
+ p! 0.66! 0.48! 0.33! 0.58! 0.12! 0.6! 0.17! 0.44!
HIVS+QFN++(n=23)+ rs! D0.12! 0.22! 0.26! 0.33! 0.09! 0.18! 0.11! 0.23!
+ p! 0.60! 0.31! 0.23! 0.18! 0.67! 0.40! 0.62! 0.37!
HIV++QFNS+(n=13)+ rs! 0.37! D0.24! 0.22! D0.18! D0.11! D0.06! 0.19! D0.32!
+ p! 0.22! 0.43! 0.48! 0.57! 0.72! 0.86! 0.53! 0.30!
HIV++QFN++(n=14)+ rs! 0.002! 0.65! D0.13! 0.45! 0.04! D0.08! 0.007! D0.29!





















































































































































HIVD! 62! 60! 54!
HIV+! 46! 46! 34!
QFN!D! 52! 51! 39!
QFN!+! 56! 55! 49!
HIVD!QFND! 27! 26! 22!
HIVD!QFN!+! 35! 34! 32!
HIV+!QFN!D! 25! 25! 17!
HIV+!QFN!+! 21! 21! 17!


















































































































































































































































































































































































































































































































Chemokine+ Antigen+ Response+at+birth+(pg/ml)+ Response+at+16+weeks+(pg/ml)+ p+
ILD1Ra! Nil! 10.91!(8.89!D!13.39)! 7.78!!(6.19!D7.78)! 0.03!
IPD10! Nil! 25.46!(20.44!D!31.71)! 167.50!(131.06!D!167.53)! <0.001!
MCPD1! Nil! 371.85!(268.47!D!515.04)! 1774.01!(1233.05!D!774.79)! <0.001!
MDC! Nil! 84.80!(77.55!D!92.73)! 128.38!(116.13!D!128.32)! <0.001!
MIPD1β! Nil! 125.22!(96.26!D!162.90)! 222.07!(165.54!D!222.14)! 0.005!
sCD40L! Nil! 105.80!(93.09!D!120.23)! 87.27!(75.67!D87.28)! 0.039!
ILD8! Nil! 202.03!(144.02!D!283.40)! 406.67!(278.57!D!406.69)! 0.008!
EGF*! Nil! 6.28!(1.6!–!12.40)! 13.39!(5.9!–!24.25)! <0.001!
ILD6*! Nil! 4.29!(1.60!–!15.38)! 10.19!!(4.35!–!47.33)! <0.001!
ILD10*! Nil! 1.60!(1.60!–!1.60)! 1.60!(1.60!–!3.84)! <0.001!
TNFDα*! Nil! 1.60!(1.60!–!4.88)! 4.81!(2.43!–!10.78)! <0.001!
ILD1Ra! BCG! 161.66!(131.39!D!198.89)! 15.96!(12.65!D!15.95)! <0.001!
ILD12p40! BCG! 34.59!(27.54!D!43.45)! 17.78!(13.79!D!17.78)! <0.001!
MCPD1! BCG! 2386.26!(1402.43!D!4060.28)! 646.78!(355.88!D!646.50)! 0.002!
MDC! BCG! 216.16!(168.16)! 33.08!(24.94!D!33.07)! <0.001!
TNFDα! BCG! 3024.21!(2512.99!D!639.43)! 1859.38!(1511.79!D!859.99)! <0.001!
IFNDγ! BCG! 7.13!(5.53!–!9.20)! 71.95!(54.02!D!71.92)! <0.001!
ILD10! BCG! 783.68!(633.80!–!969.55)! 177.68!(140.01!D!177.63)! <0.001!
sCD40L*! BCG! 1.60!(1.60!D!10.82)! 1.60!(1.60!D!1.60)! 0.02!
IPD10*! BCG! 1.60!(1.60!–!6.14)! 80.60!(1.60!–!284.80)! <0.001!
ILD1Ra! TT! 10.55!(8.33!D!13.37)! 7.40!(5.68!D7.40)! 0.026!
MCPD1! TT! 1769.78!(1071.16!D!924.03)! 453.96!(257.61!D453.99)! 0.001!
MIPD1β! TT! 234.77!(156.79!D!351.52)! 60.82!(38.57!D60.83)! <0.001!




















Cytokine!/!chemokine! Antigen! Rs! p!
EGF!!!! Nil! 0.26! <!.01!
ILD1Ra!!!! Nil! 0.54! <!.01!
IPD10!!!! Nil! 0.37! <!.01!
MDC!!!! Nil! 0.31! <!.01!
MIPD1β!!!! Nil! 0.25! <!.01!
sCD40L!!!! Nil! 0.31! <!.01!
TNFDα!! Nil! 0.46! <!.01!
ILD13!!!! Nil! 0.20! .04!
ILD1β!!!! Nil! 0.24! .01!
ILD6!!!! Nil! 0.22! .02!
GMDCSF!!!! BCG! 0.38! <!.01!
ILD1Ra!!!! BCG! 0.41! <!.01!
ILD12p40!!!! BCG! 0.35! <!.01!
IPD10!!!! BCG! 0.29! <!.01!
MCPD1!!!! BCG! 0.23! .02!
MDC!!!! BCG! 0.29! <!.01!
TNFDα!!! BCG! 0.51! <!.01!
IFNDγ! BCG! 0.27! <!.01!
ILD10!!!! BCG! 0.42! <!.01!
ILD1β!!!! BCG! 0.58! <!.01!
ILD6!!!! BCG! 0.45! <!.01!
GMDCSF!!!!! TT! 0.33! <!.01!
ILD1Ra!!!!! TT! 0.47! <!.01!
IPD10!!!!! TT! 0.45! <!.01!
MCPD1!!!!! TT! 0.25! .01!
MIPD1β!!!! TT! 0.50! <!.01!
TNFDα!!!!! TT! 0.44! <!.01!
ILD1β!!!!! TT! 0.30! <!.01!






Cytokine!/!chemokine! Antigen! Spearman! Spearman!pDval!
sCD40L!!!! Nil! 0.28! <!.01!
ILD12p40!!!!! BCG! 0.36! <!.01!
ILD8!!!!! BCG! 0.38! <!.01!
















Chemokine+ Antigen+ Maternal+response+(pg/ml)+ Infant+response+(pg/ml)+ P+
ILD1Ra! Nil! 6.93!(5.67!D!8.48)! 10.89!(8.89!D13.33)! <!.001!
IPD10! Nil! 57.37!(44.34!D!74.23)! 25.42!(19.62!D!32.95)! <!.001!
MDC! Nil! 20.58!(18.66!D!22.7)! 84.93!(76.96!D!93.73)! <!.001!
MIPD1β! Nil! 52.01!(40.18!D!67.33)! 124.83!(96.29!D!161.83)! <!.001!
sCD40L! Nil! 68.79!(60.27!D!78.52)! 105.50!(92.36!D!120.51)! <!.001!
ILD8! Nil! 42.52!(30.65!D!59.01)! 201.67!(145!D!280.48)! <!.001!
ILD1Ra! BCG! 73.07!(60.22!D!88.65)! 161.3!0(132.89!D!195.79)! <!.001!
ILD12p40! BCG! 12.33!(9.73!D!15.62)! 34.69!(27.37!D!43.97)! <!.001!
MCPD1! BCG! 4110.48!(2837.4!D!5954.75)! 2386.70!(1645.83!D!3461.06)! .04!
MDC! BCG! 58.01!(46.66!D!72.11)! 216.04!(173.69!D!268.72)! <!.001!
TNFDα! BCG! 1858.11!(1559.18!D!2214.37)! 3026.01!(2538.05!D!3607.78)! <!.001!
IFNDy! BCG! 11.90!(9.5!D!14.91)! 7.10!(5.66!D!8.9)! <!.001!
ILD10! BCG! 602.47!(492.57!D!736.89)! 781.88!(638.92!D!956.81)! .04!
sCD40L*! BCG! 3395!(2485!–!5055)! 26.71!(4.55!–!96.15)! <!.001!
ILD1β! BCG! 1847.47!(1484.18!D!2299.67)! 3573.54! <!.001!
ILD1Ra! TT! 7.46!(5.93!D!9.38)! 10.57!(8.4!D!13.3)! .005!
MCPD1! TT! 2925.65!(2011!D!4256.31)! 1774.65!(1217.93!D!2585.86)! <!.001!
MIPD1β! TT! 103.25!(72.81!D!146.42)! 234.26!(164.97!D!332.65)! <!.001!






















































































































































































































































 Anti-pertussis IgG 






























































































































































Hib! 0.57!(0.45!–!0.79)! 0.74!(0.61!–!1.00)! 23%! !!!.002!
Pertussis! 0.91!(0.61D1.20)! 1.51!(1.15!–!2.06)! 40%! <!.001!
Pneumococcus! 0.62!(0.41!–!0.77)! 0.73!(0.53!–!0.94)! 15%! .05!























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Maternal information (obtain from mother and mother’s antenatal folder for 
current pregnancy) 
 
1. Mother’s first name  
2. Mother’s surname  
3. Mother’s clinic folder number  
4. Mother’s date of birth (DD/MM/YYYY)  
5. Mother’s cell phone number   
6. Mother’s land line phone number   




8. Mother lives in: 1) brick house/other formal structure, or 2) shack 3) other  
9. Date enrolled (DD/MM/YYYY)  
10. Any known TB contact in mother? (Y/N) If yes, fill in TB contact sheet *  
11. Any symptoms suggestive of TB** or recent TB investigation in mother? Y / N  
      If yes, specify  
      
 
 
12. Previous treatment for TB (Y, N)  
13. Number of years since TB treatment (<1, 1-5y, 5-10y, >10y)  
14. Maternal chronic health condition? Y/N, Specify 
 
 
15. Maternal gravity   
16. Maternal parity  
17. Antenatal maternal HIV test (Pos, Neg, Indeterminate, not done) 
(Ask the mother to disclose status, test results checked with permission) 
 
18. Date of HIV test (DD/MM/YYYY)  
19. If initial HIV test negative, did mother had repeat HIV test (Y, N, U)**  
20. Date of repeat HIV test in mother (DD/MM/YYYY)  
21. Repeat HIV test result (Pos, Neg, Indeterminate)   
22. If HIV+:  Mother given AZT antenatally (Y, N, U)  
23. If HIV+: Date AZT started (DD/MM/YYYY)  
24. If HIV+: Gestation when AZT started  
25. If HIV+: Maternal CD4 count (abs and %)   
Maternal and Infant case report form: Antenatal and birth  
Mother/infant BCG study (Version 22/01/09) 





26. If HIV+: Date of CD4 count (DD/MM/YYYY)  
27. If HIV+: Maternal viral load (VL)? (copies / not done)     
28. If HIV+: date of viral load (VL) (DD/MM/YYYY)  
29. If HIV+: Mother HIV WHO stage at HIV testing  (I, II, III, IV) from clinical notes  
30. Maternal weight at enrolment (kg)  
31. Maternal length at enrolment (m, 2 decimals)  
  Labour and delivery details  
32. Delivery – Normal vaginal / assisted vaginal / emergency c-section  
33. List any other complications in labour / delivery eg PROM, haemorrhage  
34. Mother given NVP intrapartum (Y, N, U)  
35. Gestation of infant  
36. Name of baby (if known)  
37. Baby’s date of birth  
38. Baby’s gender (M/F)  
39. Baby’s birth weight (g)  
40. Baby’s head circumference (cm) Please measure this yourself if not done  
41. If HIV exposed: Baby given NVP at 6-72 h birth (Y, N, U)  
42. If HIV exposed: Baby given AZT after birth? (Y, N) State number of days   
43. Feeding (1) Breast only 2) breast and bottle 3) Bottle only)  




45. Stool sample obtained from mother? (Y/N)   
46. Blood taken from infant (Y/N)  
47. Blood taken from mother (Y/N)  
48. If mother HIV negative: Rapid HIV test performed with pre-and post-test counselling to 
confirm status (Y/N) 
 
49. Result of rapid test (Pos, Neg, Indeterminate)  
50. Referral to HIV services made if mother tests positive (Y/N)  
51. TST done? (Y/N)  
52. Date of next study visit? (If HIV exposed, give date in 4 weeks, if HIV-unexposed, give 
date in 6 weeks) 
 
 
* Note 1: If current household contact – do not enroll and refer to TB services for screening 
 **Note 2: Suggestive TB symptoms: cough of 10 days or longer, night sweats, chest pains, poor appetite  
































1! Y! Other!room! Y! Y! Y! !
2! Y! Other!room! Y! Y! Y! !
3! Y! Other!room! Y! Y! Y!! !
4!
!




5! Y! Other!room! Y! Y! N! !
6! Y! Other!room! Y! Y! N! What!if!baby!
sick!at!W/E?!
7! Y! Other!room! Y! Y! N! Is!this!a!life!
long!study?!





















I#use#public#toilets# # I#have#no#access#to#a#toilet# #
Other# # Specify………………………………………….#
3. What(is(your(highest(level(of(schooling?((Tick!one!only)(
No#schooling# # Matric# #












Yes# # No# #
6. What(fuel(do(you(mainly(use(for(cooking?#(Tick!one!only)#
Paraffin# # Electricity# #
Gas# # Specify………………………………..#Other##############################
7. Do(you(have(any(of(these(items(in(your(household?#(Tick!all!that!apply)#
Cell#phone# # Television# #
Landline# # DVD#player# #
Fridge# # Bicycle# #





















You#asked#me#to# # Don’t#know# #
Other# # Specify……………………………………...# #
10. Did(you(feel(free(to(say(yes(or(no(to(being(a(part(of(the(study?#(Tick!one!only)#
























No#problem# # #Specify####################################################Other# #
14. How(did(you(feel(about(having(blood(taken(from(you?((Tick!one!only)#
I#did#not#mind# # I#found#it#very#upsetting# #
! 197 
I#found#it#a#little#upsetting# # Other,#specify……………………# #
15. How(did(you(feel(about(having(blood(taken(from(your(baby?((Tick!one!only)#
I#did#not#mind# # I#found#it#very#upsetting# #


















































































































































































































































































































































































!! Mothers+ Infants+at+birth+ Infants+at+16+weeks+
!! Day+1+ Day+6+ Day+1+ Day+6+ Day+1+ Day+6+
EGF+ 1.6! 1.6! 1.6! 5.19! 2.73! 28.58!
GMSCSF+ 248.34! 761.28! 392.89! 961.71! 187.65! 1005.68!
ILS1ra+ 53.03! 84.92! 166.84! 376.89! 26.25! 32.6!
ILS12p40+ 25.75! 22.96! 46.97! 51.55! 23.89! 22.96!
ILS17+ 1.17! 1.7! 1.17! 1.17! 1.04! 8.9!
IPS10+ 53.71! 47.67! 25.33! 32.52! 253.56! 593.72!
MCPS1+ 5375.88! 5957.58! 6692.12! 6825.24! 5404.73! 6481.02!
MDC+ 92.41! 789.34! 207.83! 693.85! 141.18! 1639.24!
MIPS1β + 5053.6! 3107.32! 10000! 15450.86! 3543.55! 1699.23!
sCD40L+ 116.46! 28.99! 70.99! 22.29! 139.4! 54.32!
TNFSα + 1873.14! 1266.98! 3259.09! 1240.32! 1413.72! 1146.87!
IFNSγ + 7.35! 76.68! 3.03! 18.79! 74.32! 900.75!
ILS2+ 1.81! 1.59! 0.74! 0.95! 13.06! 1.59!
ILS10+ 458.09! 372.88! 576.1! 380.34! 125.13! 116.83!
ILS13+ 1.74! 1.97! 2.2! 3.72! 6.31! 45.77!
ILS1β ++ 1973.47! 1409.24! 2990.22! 2457.86! 3208.22! 3244.83!
ILS6+ 6411.33! 7806.25! 6769.94! 7037.16! 4844.88! 6091.45!
ILS7+ 1.6! 1.6! 1.6! 1.6! 1.6! 1.04!
















Hib( Pertussis( Pneumococcus( Tetanus(
b( SE(b( P( b( SE(b( P( b( SE(b( P( b( SE(b( P(
Infant(regression(model(
Maternal(HIV( 0.49# 0.12# <#.001# 0.38# 0.08# <#.001# 0.24# 0.10# 0.01# 0.52# 0.16# .002#
Infant(Gender( 0.10# 0.12# .39# 0.14# 0.08# .10# 00.04# 0.10# .71# 00.05# 0.16# .75#
Infant(Birth(Weight( 00.12# 0.15# .42# 0.05# 0.10# .61# 00.01# 0.12# .90# 00.06# 0.20# .76#
Maternal(Age(( 0.00# 0.01# .98# 0.02# 0.10# .03# 0.02# 0.01# .21# 0.02# 0.02# .27#
Maternal(Gravidity( 0.08# 0.12# .27# 00.02# 0.05# .66# 00.03# 0.06# .56# 0.08# 0.10# .42#
Housing(structure( 0.01# 0.12# .96# 0.11# 0.08# .17# 00.03# 0.10# .74# 00.15# 0.17# .40#
R2( .20# .26# .08# .12#
Independent(variables( Maternal(regression(model(
Maternal(HIV(( 0.39# 0.12# .002# 0.16# .010# .09# 0.25# 0.09# 0.005# 0.35# 0.16# 0.03#
Maternal(Age(( 00.01# 0.02# .52# 0.02# 0.01# .16# 0.01# 0.01# .18# 0.03# 0.02# .20#
Maternal(Gravidity( 0.10# 0.07# .17# 0.01# 0.05# .88# 00.01# 0.05# .86# .08# 0.09# .39#
Housing(structure( 00.04# 0.13# .73# 0.11# 0.09# .24# 00.10# 0.09# .28# 00.07# 0.16# .65#



























































































































































Maternal HIV Infection and Antibody
Responses Against Vaccine-Preventable
Diseases in Uninfected Infants
Christine E. Jones, BMBS, MRCPCH
Shalena Naidoo, BSc
Corena De Beer, PhD
Monika Esser, MBChB, MMed (Paed)
Beate Kampmann, MBBS, PhD
Anneke C. Hesseling, MD, PhD
INFECTIOUS DISEASES ACCOUNT FORnearly 6 million deaths world-wide annually in children youngerthan5 years.1 Immunization against
vaccine-preventable infections there-
fore remains essential to achievingMil-
lennium Development Goal 4, which
is to reduce childhoodmortality by two-
thirds.2 Before acquisition of immu-
nity, infants are protected by maternal
IgG transferred across the placenta.Ma-
ternal antibody levels, immunization,
infection, and infant gestational age can
influence the efficiency of this pro-
cess.3-7 Although maternal antibody is
essential to protect the infant in the first
months of life, maternal-specific anti-
body can also interfere with the in-
fant’s own response to vaccination.8
The high prevalence of maternal hu-
man immunodeficiency virus (HIV) in
many parts of the resource-poor world,
coupledwith successful programs to re-
duce mother-to-child transmission of
HIV, has led to increasing numbers of
HIV-exposed infants who are not HIV-
infected themselves (ie, HIV-exposed
infants).9 These infants and children
represent a vulnerable group with in-
creased rates of lower respiratory tract
infection and meningitis and up to
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Context Altered immune responses might contribute to the highmorbidity andmor-
tality observed in human immunodeficiency virus (HIV)−exposed uninfected infants.
Objective To study the association of maternal HIV infection with maternal- and
infant-specific antibody levels to Haemophilus influenzae type b (Hib), pneumococ-
cus, Bordetella pertussis antigens, tetanus toxoid, and hepatitis B surface antigen.
Design, Setting, and Participants A community-based cohort study in Khayelit-
sha,Western Cape Province, South Africa, betweenMarch 3, 2009, and April 28, 2010,
of 109 HIV-infected and uninfected women and their infants. Serum samples from
104 women and 100 infants were collected at birth and samples from 93 infants were
collected at 16 weeks.
MainOutcomeMeasure Level of specific antibody inmother-infant pairs at deliv-
ery and in infants at 16 weeks, determined by enzyme-linked immunosorbent assays.
Results At birth, HIV-exposed uninfected infants (n=46) had lower levels of spe-
cific antibodies than unexposed infants (n=54) did to Hib (0.37 [interquartile range
{IQR}, 0.22-0.67] mg/L vs 1.02 [IQR, 0.34-3.79] mg/L; P! .001), pertussis (16.07
[IQR, 8.87-30.43] Food and Drug Administration [FDA] U/mL vs 36.11 [IQR, 20.41-
76.28] FDAU/mL; P! .001), pneumococcus (17.24 [IQR, 11.33-40.25] mg/L vs 31.97
[IQR, 18.58-61.80] mg/L; P=.02), and tetanus (0.08 [IQR, 0.03-0.39] IU/mL vs 0.24
[IQR, 0.08-0.92] IU/mL; P=.006). Compared with HIV-uninfected women (n=58),
HIV-infectedwomen (n=46) had lower specific antibody levels to Hib (0.67 [IQR, 0.16-
1.54] mg/L vs 1.34 [IQR, 0.15-4.82] mg/L; P=.009) and pneumococcus (33.47 [IQR,
4.03-69.43] mg/L vs 50.84 [IQR, 7.40-118.00] mg/L; P=.03); however, no differ-
ences were observed for antipertussis or antitetanus antibodies. HIV-exposed unin-
fected infants (n=38) compared with HIV-unexposed infants (n=55) had robust an-
tibody responses following vaccination, with higher antibody responses to pertussis
(270.1 [IQR, 84.4-355.0] FDA U/mL vs 91.7 [IQR, 27.9-168.4] FDA U/mL; P=.006)
and pneumoccocus (47.32 [IQR, 32.56-77.80]mg/L vs 14.77 [IQR, 11.06-41.08]mg/L;
P=.001).
Conclusion Among South African infants, antenatal HIV exposure was associated
with lower specific antibody responses in exposed uninfected infants compared with
unexposed infants at birth, but with robust responses following routine vaccination.
JAMA. 2011;305(6):576-584 www.jama.com
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4-fold higher mortality in the first year
of life.10-13 A number of factors are likely
to contribute to this increased vulner-
ability, including socioeconomic fac-
tors, but immunological phenomena
might also be important.
To design appropriate interven-
tions for these vulnerable infants, it is
important to understand how mater-
nal HIV infection influences infant sus-
ceptibility to common pathogens. We
therefore studied the association ofma-
ternal HIV infectionwithmaternal- and
infant-specific antibody levels. Be-
cause absolute levels of antibody that
associate with protection against infec-
tion are poorly defined for a number of
specific antibodies, we assessed how
maternal HIV affects both the magni-




The study was conducted between
March 3, 2009, and April 28, 2010, in
a community health center in Khay-
elitsha,Western Cape Province, South
Africa, a rapidly expanding urban in-
formal settlement. In this context, all
women are offered voluntary counsel-
ing and testing forHIV at antenatal care
registration; the participation is con-
sistently close to 100%.14,15 In 2009, the
HIV prevalence amongwomen attend-
ing antenatal clinics was 32%, with re-
ported vertical transmission of 3.3%.14
During the study period, the Preven-
tion of Mother to Child Transmission
program consisted of dual therapy for
mothers and infants, starting with the
administration of zidovudine at 28 or
more weeks’ gestation, then zidovu-
dine for 1 month to the infant and a
single dose of nevirapine to bothmother
and infant. Mothers were eligible for
highly active antiretroviral treatment if
their CD4 countwas less than 200 cells/
µL. Exclusive infant feeding options
were encouraged and mothers were
providedwith free formula for 6months
if they chose exclusive formula feeding.
The study was approved by the
Universities of Cape Town and Stel-
lenbosch, South Africa, and the
National Health Service Research Eth-
ics Committee, England. Our study
was nested in a cohort study investi-
gating the influence of maternal HIV
and mycobacterial infection on infant
immune responses to BCG vaccina-
tion. The BCG vaccination (Danish
strain 1331, Statens Serum Institute,
intradermal vaccine) was delayed
until 6 weeks of age to allow for
determination of infant HIV infection
and to avoid BCG vaccination of HIV-
infected infants and vaccine adverse
events.16-18 Infants received all other
routine vaccines according to the
South African Expanded Program on
Immunization schedule: oral polio
vaccine (Sanofi Pasteur, Lyon,
France) at birth; combination diph-
theria, tetanus toxoid, and pertussis
vaccine, and Haemophilus influenzae
type b vaccine (DTP-Hib; Sanofi Pas-
teur); hepatitis B (Heber Biotec,
Havana, Cuba); and oral polio vaccine
at 6, 10, and 14 weeks. From July
2009, pneumococcal 7-valent conju-
gate (Wyeth, Andover, Massachu-
setts) and rotavirus vaccinations
(GlaxoSmithKline, Rixensart, Bel-
gium) were administered at 6 and 14
weeks, and diphtheria, tetanus toxoid,
and acellular pertussis vaccine com-
bined with inactivated polio vaccine
and Hib (DTaP-IPV/Hib; Sanofi Pas-
teur) replaced the DTP-Hib vaccine.
Tetanus immunization is not rou-
tinely administered to pregnant
women in this setting; therefore, no
vaccines were administered to partici-
pating mothers.
Eligibility
Womenwere eligible if they had deliv-
ered a healthy infant at the Site B Ma-
ternal Obstetric Unit within the previ-
ous 24 hours, knew the result of the
HIV test at antenatal care registration,
and were willing and able to provide
written informed consent for them-
selves and their infant. Mothers were
excluded if they were younger than 18
years (2 women), planning to move
away during the study period (8 wom-
en), did not intend to return to the rou-
tine Site B baby clinic for ongoing care
(15 women), were unwell (2 women),
had evidence of active tuberculosis or
were on tuberculosis treatment (1wom-
an), or had a current household or other
close tuberculosis contact (1 woman).
Infants weighing less than 2.5 kg or es-
timated at less than 36 weeks’ gesta-
tion (8 infants), with acute illness (1 in-
fant), or part of a twin birth (2 infants)
were excluded. Consecutive eligible
women were enrolled irrespective of
their HIV status. Once sufficient num-
bers of HIV-uninfected women were
reached (approximately 50% of the
sample), HIV-infected women were
consecutively enrolled. A study nurse
obtained written informed consent in
the participants’ home language.
Study Measures
A venous blood sample was collected
from the mother and infant within 24
hours of delivery and transported to the
laboratory within 4 hours. All infants
had a further venous blood sample col-
lected at 16weeks.Mothers who tested
negative for HIV during pregnancy had
a rapid HIV test (Abbott Determine
HIV-1/2, Toyko, Japan) at enrollment
with pretest and posttest counseling to
confirm their HIV status. The HIV-
exposed infants had an HIV polymer-
ase chain reaction (Amplicor HIV-a
DNA kit, version 1.5; Roche Molecu-
lar Systems Inc, Branchburg, New Jer-
sey) performed at ages 4 and 16weeks.
Infant vaccination status was verified
from vaccination cards (“Road to
Health” records). Serum was sepa-
rated and stored at −80°C for analysis
by standard commercial enzyme-
linked immunosorbent assays by re-
searchers blinded to maternal HIV in-
fection status andpersonal information.
Laboratory Assays
Hib capsular polysaccharide and pneu-
mococcal capsular polysaccharide spe-
ci f ic IgG were measured using
VaccZyme Human Anti-Hib and Anti-
PCP Enzyme Immunoassay kits
(MK016 andMK012, The Binding Site
Ltd, Birmingham,England).Microwells
in the pneumococcal assay were sup-
plied precoated with pneumococcal
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capsular polysaccharide antigens 1-5,
6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14,
15B, 17F, 18C, 19A, 19F, 20, 22F, 23F,
33F, and incorporated C-polysaccha-
ride antibody absorption, which con-
fers limited protection against pneu-
mococcal infection.19 Specific IgG to
Bordetella pertussis (pertussis) and
tetanus toxoid were measured using
SERION enzyme-linked immunosor-
bent assays classic kits (ESR120G and
ESR108G Serion Immundiagnostica
GmbH,Würzburg, Germany). Hepati-
tis B surface antigen was measured
using an AxSYM HBsAg (V2) kit (Ab-
bott, Wiesbaden, Germany) in a fully
automated system. All reagents, includ-
ing controls, were supplied with the
commercial kits andmanufacturer’s in-
structions were followed.
Anti-Hib antibody titers ofmore than
1.0 mg/L were regarded as protec-
tive20; pertussis titers of more than 30
Food and Drug Administration (FDA)
U/mL were regarded as positive (de-
fined by themanufacturer); tetanus an-
tibody levels were classified as provid-
ing sufficient protection if more than
0.1 IU/mL21; andmore than 10mIU/mL
was regarded as seropositive and pro-
tective against hepatitis B infection. No
level of protective immunity has been




Statistical analyses were completed
using SPSS version 18 (SPSS Inc, Chi-
cago, Illinois) and GraphPad Prism
version 5.0a (GraphPad Software Inc,
La Jolla, California). Two-sided
P!.05 was considered significant. All
comparisons were prespecified except
for the comparison of infants who had
not received all vaccinations, which
was post hoc.
The magnitude of specific antibody
response between groups was com-
pared using the unpaired t test when
data were normally distributed; inter-
quartile ranges (IQRs) are shown.
When the distribution was nonnor-
mal, data were log transformed; the un-
paired t test was used if resulting dis-
tributions were normal; and theMann-
Whitney test was used for nonnormal
data. Simple correlations were as-
sessed using Pearson or Spearman cor-
relation in the case of normal or non-
normal distribution, respectively. A
multiple linear regression model was
used to assess the relationship be-
tween the magnitude of maternal and
infant Hib, pertussis, pneumococcal,
and tetanus responses at delivery in re-
lation to maternal HIV status, treating
maternal age, gravidity, and house-
hold type (informal structure or brick
house), a proxy for socioeconomic sta-
tus in this community, as covariates. In-
fant sex and birth weight were used as
additional covariates in analyses of in-
fant responses at birth. All indepen-
dent variables were entered into the
model simultaneously (forced entry
method). Proportions were compared
using the Fisher exact test; if any cell
contained a value of zero, 1.0was added
to all cells before testing was per-
formed. Hepatitis B specific antibody
data had a binomial distribution and
therefore only the proportion of par-
ticipants with seroprotective levels of
hepatitis B–specific antibody results
were analyzed. Placental transfer was
defined as the ratio of infant-to-
mother specific IgG concentration at
birth.22 Missing data were excluded
from analysis. We did not adjust for
multiple comparisons.
Sample size was determined for the
cohort study; this substudy was pow-
ered to investigate differences be-
tween antibody responses in HIV-
exposed andHIV-unexposed infants of
at least 30%, with the prespecified hy-
pothesis that the magnitude of re-




Of 120 eligible mother-infant pairs, 11
mothers declined to participate; there-
fore, 109 maternal-infant pairs were
enrolled (91% participation rate). Of
these pairs, 47 mothers (43%) were
infected with HIV and 62 (57%) were
uninfected. All women testing nega-
tive for HIV at their antenatal care reg-
istration had a further repeat negative
HIV test at delivery. Samples were col-
lected from 105 mothers (96% of the
maternal sample; 47 were infected and
58 were uninfected with HIV) at deliv-
ery, and from 101 infants (93% of the
infant sample; 47 were exposed and
54 were unexposed to HIV) at birth.
Sample volumes were insufficient for 4
women and 8 infants. One infant (1%)
was determined to be infected with
HIV at 4 weeks and was referred for
rapid initiation of antiretroviral treat-
ment (mother-infant pair subse-
quently was excluded from analysis).
Follow-up samples were available for
94 infants (87%; 38 were exposed and
55 were unexposed to HIV) at a mean
postnatal age of 16.4 weeks (SD, 1.7).
One late follow-up sample was
excluded from the analysis (collected
at 28 weeks after birth). The final
analysis was based on samples from
104 women and 100 infants collected
at birth and samples from 93 infants
collected at 16 weeks.
Characteristics of the study cohort
are shown in TABLE 1. All HIV-
infected women chose exclusive for-
mula replacement feeding. The mean
(SD) CD4 count among the HIV-
infectedwomenwas 474 (252) cells/µL
and the median (IQR) viral load was
800 (357-6000) copies/mL. Seven
women had CD4 counts of less than
200 cells/µL; 3 of these were taking
highly active antiretroviral treatment at
enrollment and 4were referred to com-




At birth, HIV-exposed uninfected
infants had significantly lower specific
antibody levels compared with unex-
posed infants to Hib (0.37 [IQR, 0.22-
0.67] mg/L vs 1.02 [IQR, 0.34-3.79]
mg/L; P! .001), pertussis (16.07
[IQR, 8.87-30.43] FDA U/mL vs 36.11
[IQR, 20.41-76.28] FDA U/mL;
P! .001), pneumococcus (17.24 [IQR,
11.33-40.25] mg/L vs 31.97 [IQR,
18.58-61.80] mg/L; P=.02), and teta-
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nus (0.08 [IQR, 0.03-0.39] IU/mL vs
0.24 [IQR, 0.08-0.92] IU/mL; P=.006)
(FIGURE 1).
These lower levels observed in HIV-
exposed infants at birth corresponded
with a lower proportion of HIV-
exposed infants with levels consid-
ered to be protective against Hib (17%
vs 52%; P! .001), pertussis (24% vs
57%; P=.001), tetanus (43% vs 74%;
P=.002), and hepatitis B (21% vs 54%;
P=.01).
In amultiple linear regressionmodel
for factors associated with magnitude
of specific antibody response at birth,
HIV exposure remained associatedwith
reduced Hib titers (unstandardized re-
gression coefficient [b]=0.49; SE, 0.12;
P! .001), pertussis (b=0.38; SE, 0.08;
P! .001), pneumococcus (b=0.24; SE,
0.10; P=.01), and tetanus (b=0.52; SE,
0.16; P=.002) levels (eTable 1, avail-
able at http://www.jama.com). There
was no association with maternal age,
gravidity, housing structure, infant sex
or birth weight for Hib, pneumococ-
cus, and tetanus levels, but increased
maternal agewas associatedwith higher
pertussis-specific antibody titers
(b=0.02; SE, 0.01; P=.03) (eTable 1).
Maternal-Specific Antibody
Responses
To investigate the mechanisms associ-
ated with infant response, we mea-
sured specific maternal antibody levels
in parallel. HIV-infected women had
lower specific antibody levels than
uninfected women to Hib (0.67 [IQR,
0.16-1.54] mg/L vs 1.34 [IQR, 0.15-
4.82] mg/L; P=.009) and pneumococ-
cus (33.47 [IQR, 4.03-69.43] mg/L vs
50.84 [IQR, 7.40-118.00] mg/L;
P=.03). No differences were observed
for pertussis (22.07 [IQR, 12.48-
29.67] FDA U/mL vs 23.64 [IQR,
12.87-54.68] FDA U/mL; P= .26) or
tetanus (0.09 [IQR, 0.03-0.33] IU/mL
vs 0.15 [IQR, 0.06-0.67] IU/mL;
P= .12) between HIV-infected and
uninfected women. In a multiple
regression model for factors associated
with level of maternal-specific anti-
body response, maternal HIV infection
remained associated with low Hib and
pneumococcal antibody levels; how-
ever, there was no significant associa-
tion with maternal age, gravidity, or
housing structure for any of the spe-
cific antibody responses (eTable 1).
HIV-infectedwomenwere less likely
to have anti-Hib antibodies levels con-
sidered to be protective (35% vs 59%;
P=.02). The proportion of womenwith
protective antibody levels against per-
tussis (24% vs 38%; P=.14), tetanus
(47% vs 64%; P=.11), or hepatitis B
(26% vs 33%; P=.52) was similar in
HIV-infected and HIV-uninfected
women. The overall proportion of all
women with protective antibody lev-
els was low for pertussis (32%), teta-
nus (41%), and hepatitis B (30%).
In HIV-infected women, CD4 count
was positively correlated with the level
of antibody to pertussis (r=0.31;
P = .04), pneumococcus (r = 0.33;
P=.03), and tetanus (r=0.37; P=.01),
but not with Hib (r=−0.07; P= .63)
(eTable 2). Therewas no correlation be-
tweenmaternal HIV viral load and any
specific antibody level (eTable 2).
In HIV-infectedwomen and their in-
fants, the correlation between mater-
nal- and infant-specific antibody re-
sponseswere statistically significant for
Hib (r = 0.91; P! .001), pertussis
(r=0.78; P! .001), pneumococcus
(r = 0.86; P! .001), and tetanus
(r=0.95; P! .001). In HIV-negative
women, the correlation between ma-
ternal and infant responses were also
statistically significant for Hib (r=0.95;
P! .001), pertussis (r=0.89; P! .001),
pneumococcus (r=0.80; P! .001), and
tetanus (r=0.93; P! .001).
Association of Maternal HIV
With Placental Transfer
of Specific Antibody
The proportion ofmaternal-specific an-
tibody transferred across the placenta
to infants was significantly reduced
among HIV-infected women and their
infants. Using infant:maternal anti-
Table 1. Characteristics of HIV-Infected and HIV-Uninfected Women and Their Uninfected Infants
Characteristics
No. (%) of Participants
P Value
HIV-Infected Women and Exposed Infants
(n = 46 at Birth)
HIV-Uninfected Women and Unexposed Infants
(n = 54 at Birth)
Maternal age, median (IQR), y 27.0 (24.0-31.3) 24.0 (20.0-27.5) .002a
Maternal primigravidity 10 (21) 28 (45) .01b
Female infant sex 25 (57) 33 (57) .68b
Infant delivered by normal vaginal delivery 46 (100) 54 (100) ".99
Birth weight, mean (SD), kg 3.16 (0.35) 3.23 (0.44) .38c
Weight at 16 wks, mean (SD), kgd 6.81 (0.93) 6.60 (0.93) .29c
Exclusive breast feeding at birthe 0 54 (100) !.001
Exclusive breast feeding at 16 wkse 0 23 (42) !.001
Household lives in informal structuref 36 (78) 34 (54) .02b




dWeight at 16 weeks available for all infants followed up to 16 weeks (38 HIV-exposed infants and 55 HIV-unexposed infants).
eNo breast feeding was reported at any study visit for HIV-exposed infants.
fAn informal structure is a shack constructed of materials such as wood and corrugated iron.
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body ratios as a proxy for placental
transfer, HIV-infected women had sig-
nificant reductions in placental trans-
fer of 23% for Hib, 40% for pertussis,
and 27% for tetanus-specific antibod-
ies compared with HIV-uninfected
women, with a trend toward a reduc-
tion in placental transfer of pneumo-
coccal specific antibodies (TABLE 2).
AmongHIV-infectedwomen, therewas
no association between maternal CD4
count or viral load and placental trans-
fer (eTable 2).
Specific Vaccine-Induced Antibody
Responses in Infants at 16 Weeks
In stratified analysis for infants who
had received 1, 2, or 3 doses of DTP-
Hib vaccine (n = 6, 22, and 65,
respectively), there was no difference
in antibody levels between infants
who had received 1 or 2 doses (eTable
3); these groups were therefore com-
bined for further analysis. Similarly,
datawere combined for infantswhohad
received 1 or 2 doses of pneumococ-
cal capsular polysaccharide (n=15 and
34, respectively). There was no statis-
tical difference in the proportion of
HIV-exposed and HIV-unexposed in-
fants who received fewer than 3 doses
of DTP-Hib vaccine (25% vs 16%;
P=.31) or fewer than 2 doses of pneu-
mococcal capsular polysaccharide (20%
vs 49%; P= .06) before the 16-week
sampling.
Despite initially lower titers at
birth, HIV-exposed uninfected
infants mounted robust responses fol-
lowing vaccination. In the group that
received all 3 scheduled doses of
DTP-Hib vaccine, HIV-exposed
infants had significantly higher
responses to pertussis (270.1 [IQR,
84.4-355.0] FDA U/mL vs 91.7 [IQR,
27.9-168.4] FDA U/mL; P=.006) than
unexposed infants did (FIGURE 2),
but had similar responses to Hib and
tetanus. HIV-exposed infants also
had higher levels of pneumococcal-
s p e c i f i c a n t i b o d y t h an H IV -
unexposed infants did (47.32 [IQR,
32.56-77.80] mg/L vs 14.77 [IQR,
11.06-41.08] mg/L; P=.001). Among
infants who had received only 1 or 2
doses of DTP-Hib vaccine, responses
were higher in the HIV-exposed
infants than unexposed infants to
Hib (6.46 [IQR, 1.74-9.29] mg/L vs












































































































HIV indicates human immunodeficiency virus; FDA, Food and Drug Administration. Specific antibodies to Hae-
mophilus influenzae type b (Hib), Bordetella pertussis antigens, pneumococcus, and tetanus toxoid from serum
samples collected within 24 hours of birth were nonpreferentially analyzed on available sample volume by com-
mercially available enzyme-linked immunosorbent assays. Horizontal lines indicate median response. The Mann-
Whitney U test was used to compare antibody levels at birth between HIV-exposed and HIV-unexposed infants.
Table 2. Influence of Maternal HIV Infection on Placental Antibody Transfer
Specific Antibody
Placental Transfer, Median (IQR)a





Haemophilus influenzae type b 0.57 (0.45-0.79) 0.74 (0.61-1.00) 23 .002
Bordetella pertussis 0.91 (0.61-1.20) 1.51 (1.15-2.06) 40 !.001
Pneumococcus 0.62 (0.41-0.77) 0.73 (0.53-0.94) 15 .05
Tetanus toxoid 0.95 (0.60-1.12) 1.30 (1.03-1.86) 27 !.001
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range.
aPlacental transfer of antibody from mother to infant is expressed as a ratio of infant/maternal specific IgG concentration at birth.
bPercentage reduction in placental transfer between HIV-infected and HIV-uninfected women; calculated as the ratio of the placental transfer from HIV-infected women:placental
transfer from HIV-uninfected women, subtracted from 100.
cMann-Whitney U test.
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0.54 [IQR, 0.24-4.10] mg/L; P=.02),
pertussis (81.16 [IQR, 38.64-195.40]
FDA U/mL vs 11.60 [IQR, 5.30-
39.42] FDA U/mL; P! .001), and
tetanus (1.86 [IQR, 0.51-2.21]
IU/mL vs 0.50 [IQR, 0.10-0.93]
IU/mL; P=.01) (Figure 2).
The fold increase in antibody level
before and after vaccination was sig-
nificantly higher in the HIV-exposed
infants than in the HIV-unexposed
infants for Hib (21.15-fold increase
[IQR, 6.84-118.40] vs 2.97-fold
increase [IQR, 0.71-16.69]; P=.007),
pertussis (9.51-fold increase [IQR,
2.80-24.25] vs 2.16-fold increase
[IQR, 0.41-6.84]; P=.002), and pneu-
mococcus (2.06-fold increase [IQR,
0.96-5.70] vs 0.31-fold increase [IQR,
0.26-1.04]; P! .001). There was no
difference in the fold-increase at pre-
vaccination and postvaccination
between the 2 groups for tetanus-
specific responses (14-fold increase
[IQR, 3.26-116.20] vs 12- fo ld
increase [IQR, 2.8136.35]; P=.54).
FIGURE 3 shows prevaccination and
postvaccination antibody levels for in-
dividual infants. Infants with the low-
est levels of anti-Hib, pertussis, pneu-
mococcal , and tetanus-specif ic
antibodies showed the greatest vac-
cine responses at 16 weeks. HIV expo-
sure was associatedwith a greatermag-
nitude of change between birth and 16
weeks.







































































































































HIV indicates human immunodeficiency virus; FDA, Food and Drug Administration. Specific antibodies to Haemophilus influenzae type b (Hib), Bordetella pertussis
antigens, pneumococcus, and tetanus toxoid from serum samples collected at 16 weeks were analyzed by enzyme-linked immunosorbent assays. Three vaccine doses
indicate when the vaccine schedule was complete with vaccines administered at 6, 10, and 14 weeks; and 1 or 2 vaccine doses indicate when the schedule was in-
complete (except pneumococcal vaccination, for which only 2 doses were scheduled before 16 weeks). Samples were collected from 93 infants at 16 weeks (38 HIV-
exposed infants and 55 HIV-unexposed infants) and antibody levels were nonpreferentially completed on available sample volume. The number of samples analyzed
for each exposure group in each vaccine dose group is indicated. Horizontal lines indicate median response. For anti-Hib IgG, P=.70 for uninfected HIV-exposed
infants vs HIV-unexposed infants at 3 vaccine doses; P=.02 for uninfected HIV-exposed infants vs HIV-unexposed infants at 1 or 2 vaccine doses; P=.21 for unin-
fected HIV-exposed infants at 3 vaccine doses vs 1 or 2 vaccine doses; and P=.001 for HIV-unexposed infants at 3 vaccine doses vs 1 or 2 vaccine doses. For anti-
pertussis IgG, P=.006 for uninfected HIV-exposed infants vs HIV-unexposed infants at 3 vaccine doses; P! .001 for uninfected HIV-exposed infants vs HIV-
unexposed infants at 1 or 2 vaccine doses; P=.09 for uninfected HIV-exposed infants at 3 vaccine doses vs 1 or 2 vaccine doses; and P! .001 for HIV-unexposed
infants at 3 vaccine doses vs 1 or 2 vaccine doses. For antipneumococcal IgG, P=.001 for uninfected HIV-exposed infants vs HIV-unexposed infants. For antitetanus
IgG, P=.71 for uninfected HIV-exposed infants vs HIV-unexposed infants at 3 vaccine doses; P=.01 for uninfected HIV-exposed infants vs HIV-unexposed infants at
1 or 2 vaccine doses; P=.43 for uninfected HIV-exposed infants at 3 vaccine doses vs 1 or 2 vaccine doses; and P! .001 for HIV-unexposed infants at 3 vaccine doses
vs 1 or 2 vaccine doses.
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COMMENT
Toour knowledge,wepresent themost
comprehensive study to date evaluat-
ing the association of maternal HIV
infection and maternal-specific anti-
body levels and infant antibody re-
sponses to routine World Health
Organization Expanded Program on
Immunization vaccines. We demon-
strate that HIV-exposed uninfected
infants have lower specific antibody
levels at birth than their non–HIV-
exposed peers. Similarly, a smaller pro-
portion of these infants have levels
deemed to be protective.We show that
this is due to a combination of factors:
lower antibody titers to Hib and pneu-
mococcus in HIV-infected pregnant
women and reduced transplacental
transfer of Hib, pertussis, pneumococ-
cal, and tetanus-specific antibodies.
Ourdata alsohighlight low levels of spe-
cific antibody inHIV-uninfectedwomen
with the consequence that half of their
infants may not be sufficiently pro-
tected against Hib and pertussis early
in life.
Our findings are consistent with 2
studies in HIV-infected women from
Kenya, indicating that maternal HIV is
associatedwith lower tetanus andmea-
sles–specific antibody in cord blood and
also with reduced placental antibody
transfer.4,23Maternal tetanus-specific an-
tibody levels are lower among HIV-
infected women in some studies; in-
consistencies observed may be due to
differences in vaccination practice dur-
ing pregnancy.4,7
Although it is known that measles,
Hib, and pneumococcal vaccine re-
sponses are reduced in children in-
fected with HIV, there is a paucity of
studies investigating the influence
of infant HIV exposure (in the ab-
sence of infection) on responses to vac-
cines.24-28Weobserved an increased vac-
cine response in HIV-exposed infants
to pertussis and pneumococcus com-
pared with HIV-unexposed infants fol-
lowing completion of the immuniza-
tion schedule. This can be explained by
the lower maternally derived antibody
levels at birth. Conversely, higher
levels of maternal antibody among
HIV-unexposed infants at birth corre-
spondedwith lower responses postvac-
cination. Other studies have also re-
ported that maternal antibodies can
inhibit infant response tomeasles, teta-
nus, whole cell pertussis, and Hib vac-
cines; this effect varies considerably be-
tween different vaccines and studies.8,29
The mechanisms through which ma-
ternal antibodies inhibit infant re-
sponses to vaccination are not fully
understood. However, a plausible ex-
planation is that maternal antibodies
mask or hide vaccine antigenic epi-
topes, preventing recognition and bind-
ing by infant B cells; a key determi-
nant of infant responses appears to be
the maternal antibody-to-vaccine an-
tigen ratio.30
HIV-exposed infants who had
missed doses of vaccine before sam-
pling at 16 weeks had higher antibody
responses than HIV-unexposed infants
to Hib and tetanus, as well as pertussis
and pneumococcus. An explanation
for this observation is that higher
maternal antibodies observed among
HIV-unexposed infants may influence
the response to the first dose of vac-
cine but not to subsequent doses. A
study in Finland31 reported a similar
effect; infants with high levels of
maternally derived antibody had lower
anti-Hib antibody after the first dose of
Hib vaccination, but not after the sec-
ond dose.
A limitation of our study is enroll-
ment at a single center with a modest
number of mother-infant pairs. Sam-
plingwas however consecutive and rep-
resentative of women and infants ac-
cessing care in this community setting.
We did not have data onmaternal vac-
cination history, due to limitations in
recall and documentation. Vaccina-
tion records in this setting are typi-
Figure 3. Change in Specific Antibody Titers Between Birth and 16 Weeks in Uninfected



























































































HIV indicates human immunodeficiency virus; FDA, Food and Drug Administration. Each infant is represented by
a vertical bar that starts at the specific antibody level at birth and ends in the specific antibody level at 16weeks; the
length of the bar reflects themagnitude of the vaccine response. The infants are ordered by specific antibody level
at birthwith specific antibodies toHaemophilus influenzae type b (Hib), pertussis, pneumococcal capsular protein,
and tetanus.Results are shown for infantswho received3dosesof combinationdiphtheria, tetanus toxoid, andper-
tussisvaccineandHib(DTP-Hib)or2dosesofpneumococcalconjugatevaccineforwhompairedsampleswereavailable.
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cally available for young children only.
Women in our study groups had sta-
tistically different but clinically com-
parable ages; therefore, similar mater-
nal vaccination history between groups
could be inferred based on the date of
the introduction of the universal Ex-
panded Program on Immunization
schedule in South Africa (1973).
Although antibody levels can be used
to indicate potential susceptibility to in-
fection, some uncertainty remains re-
garding the functional relevance of a
single so-called protective level. In ad-
dition, protective levels for collective
response tomultiple pneumococcal se-
rotypes are unclear and there is a pau-
city of evidence for defining protec-
tive levels for other antibodies such as
pertussis.32 Functional assaysmay give
a better assessment of the ability of the
immune system to effectively clear a
pathogen. Further work to address this
aspect is ongoing.
We were unable to correlate anti-
body levels with long-term vaccine re-
sponses or clinical outcomes in the
women or infants. However, our data
contribute to a potential explanation for
the highermorbidity andmortality ob-
served among AfricanHIV-exposed in-
fants. For example, the lower ob-
served pneumococcal-specific antibody
amongHIV-exposed infants before vac-
cination might be associated with in-
creased severity of pneumonia ob-
served in this group of infants.12 Our
data highlight the need for larger pro-
spective studies to determine whether
the lower antibody levels in HIV-
exposed infants at birth translate into
increased morbidity from vaccine-
preventable infections.
Our study results also support the
evaluation of novel maternal and neo-
natal immunization strategies to aug-
ment specific antibody responses and
potentially prevent infections in in-
fants in early life, particularly in HIV-
exposed infants. In view of similar de-
ficiencies also observed in the non–
HIV-exposed group, benefits may exist
for these infants too.
The implementation of vaccination
programs in pregnancy, although re-
sulting in decreased infant and mater-
nal morbidity, is challenging because
immunization in pregnancy may im-
pair infant responses to vaccination as
a result of increased maternal anti-
body.21,33,34 Evaluation of pneumococ-
cal or pertussis vaccination strategies
during pregnancy, or before preg-
nancy, in settings with high preva-
lence of HIV howevermay benefit both
mother and child.35-39 An alternative and
feasible strategy is neonatal vaccina-
tion. For example, neonatal pertussis
vaccination is safe and results in early
antibody responses; however, re-
sponses to Hib and hepatitis B vac-
cines may be affected.40 The timing of
neonatal vaccinations therefore needs
to be carefully considered.41 We rec-
ommend evaluation of both maternal
and neonatal vaccination strategies, as
each has merits and challenges.
In conclusion, our study describes
specific antibody responses inmother-
infant pairs with and without mater-
nal HIV infection before and after in-
fant vaccination and elucidates
mechanisms for reduced responses in
HIV-exposed uninfected infants early
in life. A significant percentage of non–
HIV-infected women also showed in-
sufficient protection. Larger prospec-
tive studies are needed to ascertain the
relationship between these observed im-
mune responses and clinical end points.
Targeted vaccination strategies may be
required in HIV-infected women and
their infants.
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INTRODUCTION
Tuberculosis (TB) in children most commonly results from
exposure to a household contact with active TB, and represents
ongoing transmission of Mycobacterium Tuberculosis (Mtb) in the
community.1 Infants and young children have an increased risk of
infection following exposure and progress more readily from
infection to active TB disease; in the absence of intervention, infants
havea 50-60% riskof disease in thefirst year following infection.2,3 It
could therefore be argued that the determining factor for the higher
susceptibility to disease in children is prolonged, intimate contact
between the child and the index case, which might lead to a larger
inoculum of Mtb. However, there is little evidence to support this
assumption, since the mycobacterial load in children is notoriously
low, which lies at the root of the problem of bacteriological
confirmation of primary TB. Young children more commonly
present with disseminated disease and have an increased risk of
death.2 Even low bacillary loads in children can lead to acute and
severe illness, be it respiratory or disseminated, especially in
children younger than 2 years of age. The generally accepted
assumption is therefore thatqualitative andquantitative differences
in the immune responses to Mtb infection between adults and
children determine outcome. In the following review, we describe
the multiple factors involved in containment of mycobacteria and
review potential differences between responses in adults versus
children. We have chosen to base this article primarily on studies
conducted in the humanhost and -where available - in children. It is
however obvious that crucial data on the impact of age on many of
the cited factors are missing from the published literature, and we
indicate where further studies would be warranted in this context.
PATHOGENESIS - A BRIEF OVERVIEW
A child in close contact with an infectious index casemay inhale
Mtb aerosolised in infected droplets. Should the bacilli be
successful in traversing the physical and anatomical barriers
encountered,Mtb bacilli are inhaled into the terminal alveoli. Once
in the terminal alveoli, Mtb is readily phagocytosed by resident
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alveolar macrophages and dendritic cells. This process of inter-
nalisation results in activation of antimicrobial mechanisms,
which serve to limit the growth of Mtb and recruit additional
immune cells. Bacilli are processed and presented on the cell
surface by antigen presenting cells that migrate to regional lymph
nodes and present the Mtb antigens to T cells. Secretion of
cytokines, such as IL-12, causes CD4+T cells to proliferate and
secrete IFNg, which further activates macrophages to become
microbicidal. The fate of Mtb within the macrophage leads to four
possible outcomes; Mtb infection can either cause primary TB
disease, become dormant (‘‘latent TB’’, LTBI), be eliminated or
reactivate later to cause disease. Factors assigned to innate as well
as acquired immune responseswill determine the outcome, aswell
as the mycobacteria themselves. We acknowledge that the
compartmentalisation of immune mechanisms into innate and
adaptive immune responses is increasingly artificial, and we
describe below the elements associated with both ‘‘arms’’ of this
response, but also relay their close interplay.
FIRST OBSTACLES
Antimicrobial peptides, proteins and neutrophils
Following inhalation, Mtb is initially exposed to antimicrobial
peptides (defensins, cathelicidins) and proteins (lactoferrin,
lysozyme) in respiratory secretions with both bactericidal and
immunomodulatory effects.4 These peptides and proteins are
produced by multiple cell types including neutrophils, monocytes,
macrophages, T cells and epithelial cells.4,5 They are present in the
airways from the early neonatal period, but their relevance in
paediatric tuberculosis is yet to be established and normal age-
ranges for these substances do not exist.6
Cathelcidin canbe inducedbyvitaminD.Mtb stimulates Toll-like
Receptor 2 (TLR2), a pattern recognition receptor (PRR), which in
turn increases the expression of vitamin D receptor and causes the
conversionofvitaminDto itsactive formfacilitating the inductionof
anti-mycobacterial cathelcidin.7 The interplay between vitamin D
status, TLR function and antimycobacterial peptides warrants
further investigation in the context of childhood TB, particularly
since clinical data show that vitaminDdeficiency is very common in
childrenwith TB.8However,whether vitaminDdeficiency is a result
of TB or a contributor to susceptibility remains to be established.
Collectins
Collectins are soluble proteins which include mannose-binding
lectin (MBL), surfactant protein A (SP-A) and surfactant protein D
(SP-D).9 These form a first line of defence againstMtb by binding to
mycobacteria and thereby affecting uptake, killing and innate
immune receptor expression. In particular, MBL bindsMtb capsular
lipoarabinomannan (LAM) leading to opsonisation, complement
activation and enhanced Toll-Like Receptor (TLR) signalling. Their
relevance is demonstrated by increased susceptibility to Mtb in
individuals with polymorphisms in the SP-A gene and abnormal
levels of serumMBL.10 SerumMBL peaks at 1month of age and then
decreases to adult levels by 12 years of age.11 Low MBL has been
shown to have a protective effect in Mtb infection, suggesting that
age related changes in MBL levels may have an effect on patterns of
disease in childhood.12
Complement and complement receptor
Mtb can activate complement pathway in a variety of ways and
can also bind complement receptor 3 (CR3) directly thus
facilitating uptake by macrophages.13–15 Uptake via CR3 leads to
a different pathway of macrophage activation compared to uptake
via Fc receptors.15 Complement components are relatively low in
the neonatal period but approach adult levels by 6months of age.16
How these age related changes affect susceptibility to tuberculosis,
or patterns of disease, is yet to be investigated.
Neutrophils
Neutrophils are abundant in the BAL fluid of adults with
pulmonary tuberculosis and frequently contain mycobacteria in an
active state of division.17 They are an early feature during granuloma
formationandonstimulationwithmycobacterialantigens,producea
number of cytokines and chemokines, which can potentially
influenceadaptive immuneresponses.18Thepotential forneutrophil
mediated mycobacterial killing is debated but has been demon-
strated in vitroand anumber of neutrophil products aremycobacter-
icidal. In adults, the risk of latent tuberculosis infection following
contact with active pulmonary TB has been shown to be inversely
proportional to baseline neutrophil count.19
Together these observations suggest a substantial role for
neutrophils in the control and/or pathogenesis of Mtb infection.
Quantitative and functional differences in blood neutrophil
populations are well recognised during the neonatal period.20
What contribution these differences might have on the pattern of
Mtb disease observed in children has not yet been investigated.
ANTIGEN PROCESSING AND PRESENTATION
Macrophages
Having survived these first obstacles of innate effector mechan-
isms, Mtb is engulfed by macrophages in the terminal alveoli,
primarily by the binding ofMtbwith CR3.21 Mycobacterial cell wall
products are recognized by TLR 2 and 4, resulting in activation of a
cascade of signalling molecules including myeloid differentiation
factor 88 (MyD88). This series of events cumulates in the activation
of NFkB that ultimately triggers the synthesis of inflammatory
cytokines and chemokines that elicit a specific immune response.
In addition to the recruitment of CD4+ T cells by the action of IL-
12 from macrophages and dendritic cells, these inflammatory
cytokines recruit multiple other cell types to the locality, such as
natural killer (NK) cells and gd cells, which also secrete cytokines
to activate infected macrophages (discussed further below).
Whilst childrenhavesimilarnumbersofalveolarmacrophagesby
24-48 hours of life, their function is impaired with deficient
macrophage phagocytosis and recruitment during early childhood
with consequences for the initiation of an antigen-specific
response.22
Dendritic cells
Dendritic cells (DC) are highly efficient antigen presenting cells
(APC). As such, they play an essential role in the initiation of the
antigen-specific T cell response.23Mtb infects DCs by binding to the
DC-specific C-type lectin (DC-SIGN) in addition to CR3 and
mannose receptor. The process of internalizing Mtb results in
activation and maturation of the DC as characterized by
upregulation of major histocompatability complex (MHC) class
II molecules, co-stimulatory molecules, CD54, CD40, and B7.1 and
secretion of IL-1, IL-12 and TNF-a.23
Activated DCs migrate to the draining lymph nodes by a CCL19/
21 dependant mechanism where they mature and present
processed Mtb antigen on surface MHC class II to CD4+T cells
with the aid of co-stimulatory molecules, thereby inducing the
adaptive immune response.23
Infants have fewer circulating DCs than adults and their
functional capacity is reduced.24 In particular, the ability of DCs to
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present antigen to naı¨ve T cells appears to be reduced until the
second year of life.22
Once inside the lymph node, the matured DCs present MHC-
peptide complexes to T cells via the T cell receptor (TCR) and, along
with co-stimulatory molecules such as CD80 and CD86 and
cytokines such as IL-12p70, trigger naı¨ve T cells to proliferate and
differentiate.
The capacity to produce IL-12p70 is markedly reduced at birth,
and its synthesis by peripheral blood mononuclear cells continues
to be impaired compared to adult levels until 12 years of age.25,26
Whilst cord blood DC numbers are attenuated compared to DC
numbers observed in adults, this alone is not sufficient to explain
the marked reduction in IL-12p70 producing capacity.26 Increased
IL-10 production may play a role in the reduction in the neonatal
period, however IL-10 levels measured in cell culture supernatants
in childhood and adolescence are comparable to those found in
adulthood.26 The relative impairment in IL-12p70 synthesis can be
overcome by the provision of DCmaturational signals, GM-CSF and
IL-4, suggesting that it is the immaturity of DCs which limits the
synthesis of IL-12 and the initiation of a type 1 (Th1) type response
rather than an intrinsic defect.26 Other studies have further
characterized this deficiency as a defect in IL-12(p35) gene
expression.25 Along with the relatively poor antigen presenting
capacity of DCs, impaired IL-12 function may in turn translate into
increased susceptibility to TB in children.
THE ROLE OF DIFFERENT LYMPHOCYTE POPULATIONS
CD4+ T cells
Both experimental and clinical evidence suggest that T cell
immunity is critical for control ofMtb infection, in particular CD4+
T cells. Mtb-specific CD4+ T cells primarily produce Th1 cytokines,
which include IFNg, IL-2 and TNFa. Studies of human immune
deficiencies associated with disseminated mycobacterial disease
reveal that IFNg is critical for optimal activation of macrophages
and hence for protection against TB.27,28 A group of disorders
termed ‘Mendelian Susceptibility to Mycobacterial Disease’
(MSMD) all affect Th1 cytokines, i.e. the IFNg/IL-12 pathway,
are associated with severe disease caused by mycobacteria, and
often manifest in childhood.
Conditions in which CD4+ cells are depleted, such as HIV, are
recognised to lead to increased susceptibility to TB infection and
severe TB disease, but IFNg is not an absolute correlate of
protection.29 Although immune reconstitution with anti-retroviral
medication leads to normalization of CD4+ numbers in HIV-
infected individuals, this is not associated with significant
increases in production of IFNg in response to mycobacteria.30
Although children have higher natural levels of CD4+ T cells, these
cells do not confer equal protection compared with adults, if
measured by antigen specific production of IFNg.26 Healthy adults
with LTBI demonstrate strong Mtb-specific IFNg responses in
comparison to adults with active TB, but children have poorer
responses, particularly when suffering from disseminated dis-
ease.31,32 Disseminated forms of TB such as tuberculousmeningitis
(TBM) or miliary TB have also been associated with weaker Mtb-
specific IFNg responses than pulmonary TB in children. However, it
is not clear if this is causal or as a result of disease.
Neonatal CD4+ cells exhibit reduced capacity to express Th1-
effector function, partly attributed to hypermethylation of the
proximal promoter of the IFNg gene.33 This results in a highly
restricted pattern of IFNg response to a variety of stimuli. A type 2
(Th2) response with production of IL-4, IL-10 and IL-5 appears to
predominate in the neonatal period as demonstrated by antigen-
specific T cell responses to diphtheria-tetanus-acellular pertussis
vaccine and studies of children with congenitally acquired CMV
and Herpes infection.34 However, BCG vaccination is able to induce
a robust Th1 type response already at birth.35
The production of IFNg by antigen-specific T cells as a
diagnostic tool has been exploited in the development of the
interferon gamma release assays (IGRA), which are discussed in
more detail elsewhere in this review series. Briefly, these may not
be as useful in children compared to adults, possibly due to the
age-related differences discussed here. In the early stages of
primary TB, the pool of antigen-specific effector T cells, the read-
out for the IGRA, is only beginning to be established, unlike during
reactivation disease seen in adults, where an existing effector
memory pool simply requires to be resurrected.36
While it is clear that CD4+ T cells and Th1 cytokines are critical
in the cell-mediated response to Mtb, it is also apparent that this
part of the immune response alone is not enough. Due to the
availability of better laboratory assays that allow the simultaneous
measurements of T cell populations and cytokines in small blood
samples, the role of other T cell subsets, cytokines and chemokines
are now beginning to be better defined.
CD8+ T cells
While both CD4+ and CD8+ T cells produce cytokines that
activate macrophages and lead to granuloma formation (IFNg/
TNFa), CD8+ T cells also have a directly cytotoxic effect and express
microbicidal perforins and granulysins.37 Granulysins are pro-
duced by CD8+ T cells, NK cells and gd T cells and can kill extra-and
intracellular mycobacteria, the latter in conjunction with perforin.
Mtb specific CD8+ T cells are expanded in adults with tuberculosis,
however little is known of their role in children. The limited
paediatric studies of CD8+ T cells to date suggest that specific CD8+
T cell responses may be limited in children compared with adults.
For example HIV-specific CD8+ T cell responses are infrequently
detected in infants under 1yr.38 One small study of 16 children
demonstrated increased proportions of CD8+ T cells in children
with active TB but these cloneswere CD8+CD45RA+CCR7! (naı¨ve) T
cells with weak IFNg secretion.39 Further studies are necessary to
elucidate the importance of the CD8+ T cells in the paediatric
immune response to TB.
Polyfunctional T cells have been associated with more effective
control of murine intracellular infections including Mtb.40 Recent
studies have identified polyfunctional T cells in patients with TB
and as part of induced responses to novel TB vaccine antigens, but
further studies regarding the mechanism of induction of these
polyfunctional T cells and their role as a correlate of protective
immunity are required.41,42 Whether age-related differences in
these T cell populations might explain some of the increased
susceptibility of younger children to TB remains to be established.
BRIDGING INNATE AND ADAPTIVE IMMUNITY
gd, Th17 and regulatory T cells (Tregs)
gd T cells are a further source of IFNg and granulysins as part of
the immune response to TB.43 While CD4+/CD8+T cells recognise
mycobacterial peptides in the context of the MHC Class I or II, gd T
cells recognise non-proteinaceous antigens. Vd2+ subset of gd T
cells are the dominant gd T cell subset in healthy adults and
constitute a link between innate and adaptive immunity to Mtb,
responding rapidly by producing cytokines without extensive
requirements for antigen processing and presentation. Vd2+ cell
dysfunction and anergy have been described in tuberculosis, and
adult studies have shown decreased function in patients with TB
versus healthy controls as measured by mycobacterial antigen-
specific production of IFNg.44 Studies in children demonstrated an
increased proliferation of gd T cells in TB cases compared to
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healthy children, however this was also associated with decreased
production of IFNg and granulysin.43
Recent adult and murine studies have demonstrated that gd T
cells are also major producers of IL-17, in response to Mtb.45 IL-17
is a potent neutrophil recruiting agent and is responsible for much
of the inflammatory damage previously ascribed to the Th1
cytokine response. Recent studies have identified a distinct CD4+ T
cell subset, Th17, which produces IL-17 in response to mycobac-
terial antigens and participates in the protective immunity against
Mtb.46 Initial studies of adults with active TB disease compared to
healthy donors, show reduced Mtb-specific Th17 response,
possibly due to suppression by Th1 cytokines.47 IL-17 has not
been studied in the context of TB in children, but is found to be
increased in children with chronic inflammation, including
inflammatory bowel disease and juvenile idiopathic arthritis.48
Th17 cells develop from naı¨ve CD4+ T cell precursors in the
presence of TGFb and IL6. In the absence of IL6, TGFb stimulates the
development of CD4+CD25+Foxp3+ regulatory T cells (Treg).49 Tregs
are immune modulators that produce IL-10 and TGFb, both known
to suppress Th1 and Th17 responses. In adult patients, Tregs are
expanded in blood anddisease sites.50 Their role in paediatric TBhas
not yet been fully elucidated, and further studies are ongoing.
Natural Killer cells
A further cell group linking innate and adaptive immune
responses, like gd T cells, are Natural Killer [NK] cells. The vast
majority are cytotoxic and produce granulysin to lyse cells, and the
remaining 5-10% are IFNg producing. Recent evidence shows that
activated NK cells reduce Treg expansion by direct lysis of MTB-
specific Treg cells, favouring Th1 responses.51 In adults with TB
disease however, decreased NK cell activity and increased Treg
numbers have been noted.52 Paediatric studies measuring
granulysin have identified decreased production in children with
active TB disease. These levels returned to normal after che-
motherapy.53
B cells and antibody
B cells and antibody have long been considered to be of
secondary importance in Mtb immunology, but it is now
recognised that B cells may well have a general immunomodu-
latory role through antigen presentation, co-stimulation and
cytokine production [Figure 1]. Sub-groups of B cells with effector
and regulatory function- analogous to T cells- have been
postulated, although not yet in the context of TB.54 Antibody
isotype and the type of FcR involved in an immune response both
affect patterns of T cell activation/inhibition and potentially
influence disease outcome.55 There are well known deficiencies in
the antibody responses to T cell-independent antigens in children
under 2 years of age, but whether this plays a role in relation to
antibody-responses to mycobacterial antigens and the pattern of
disease in childhood is yet to be explored.56 Whether there is a
place for antibody-profiling in immunodiagnostics in children
remains to be established.
EVASION of the immune response- The mycobacteria matter too
Mtb and the human host have co-evolved over thousands of
years. It is therefore unlikely that the outcome of mycobacterial
infection is solely determined by the host response. Mtb has
developed several strategies to evade mycobacterial control by
macrophages, although few of these mechanisms have been
explored in children in particular.
[()TD$FIG]
Figure 1. This figure illustrates the key components of innate and adaptive immune mechanisms in the response to Mycobacterium tuberculosis (Mtb)
Innate defense molecules in the airways facilitate the phagocytosis of Mtb by macrophages and dendritic cells (antigen presenting cells, APCs) and Toll-like receptor (TLR)
signaling. Mtb is processed within the APC and presented to CD4 cells in regional lymph nodes on major histocompatability complex (MHC) class II molecules. IL-12 is
secreted by APCs, which causes CD4 cells to proliferate and produce IFNg. IFNg, produced by CD4 cells, CD8 cells, NK cells and gd cells activates the APC to become
microbicidal. Othermolecules such as perforins and granzymes, produced by CD8 cells, NK cells and gd cells, also facilitate destruction ofMtb bacilli. T regulatory (Treg) cells,
Th17 cells and B cells act to modulate the immune response to Mtb.
(Illustration ! Hugh Gifford 2010).
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A describedmechanism is evasion of autophagywherebyMtb is
able to reduce the fusion of infected phagosomes with lysosomes
thereby avoiding destruction by lysosomal hydrolyases and
enabling the pathogen to survive within the infected cell.57. The
mechanisms by which activated macrophages act locally to inhibit
intracellular growth of Mtb are as yet incompletely understood
(reviewed in 58).Mtb is also able to inhibit antigen presentation to
CD4+ T-cells through inhibition of MHC II expression thereby
subverting induction of the adaptive response and allowing it to
reside within macrophages within granulomas.59 Furthermore,
suppression of T cell function via the IL-6 receptor has recently
been described.60 Interesting differences between a variety of
strains of Mtb to induce - or downregulate- key cytokine profiles
have been described.61
Summary notes
The increased risk of active TB, especially of disseminated
disease probably results from differences in immune responses
between children and adults at several levels: deficiencies in
macrophages and DCs delay the recruitment of antigen-specific T
cells to primary and secondary sites of infection. Less efficient
antigen presentation in the lymph nodes by DCs may result in
decreased production of key cytokines, which in turn limits the
activation of macrophages. This may allow the organism to
proliferate to a greater extent and overwhelm the primary lung
immune responses. What mechanisms in detail might then lead to
dissemination of disease from the lung to other organs remains to
be fully established.
The described differences in immune profiles between adults
and children and between children of different ages are likely to
have implications for the design and use of immunodiagnostic
tests for TB.More detailed studies of all components of the immune
response and their relationship to age will need to inform the
development of novel assays suitable for children.
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To overcome the limitations of our knowledge with regards
to different immune mechanisms in tuberculosis, we require
! To evaluate the impact of age on immune mechanisms
deemed to be important for control of mycobacteria
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Introduction
Although significant progress towards Millennium
Goals 4 and 5 has been recorded, neonatal mortality
remains a global challenge. There were an estimated
3.3 million neonatal deaths worldwide in 2009,
accounting for a significant proportion of under-5-
year mortality. Progress in this age group is now most
urgently required.1 Infectious diseases are the major
cause of neonatal deaths and some can be prevented
by vaccination, which is accepted as one of the most
successful and cost-effective health interventions.
However, to achieve full protection against infections
requires multiple doses of vaccines given over several
months in the first year of life.
During this particularly vulnerable period of early
infancy, newborns remain partially protected through
transfer of immunoglobulins from the mother, which
carry specific antibodies against infections or vaccine
antigens that the mother had previously encountered.
However, maternal levels of such specific immunoglo-
bulin (IgG) are frequently sub-optimal.2 Maternal
immunisation represents a strategy that could be
employed to ‘bridge the gap’ in protection: the aim is
to enhance the antibody levels against a particular
infectious disease by giving the vaccine to the pregnant
woman, who will then transmit a protective level of
antibody to her infant in utero and through breastmilk
after birth. Multiple factors can affect the transfer of
IgG across the placenta, including maternal IgG
concentration, the IgG subtype, gestational age and
maternal co-infections, such as HIV.3 These factors,
among others, also determine the level of immunity
that an infant can obtain from a maternal vaccine.
Successful examples of achieving infant protection
through maternal immunisation are maternal vacci-
nation against tetanus, which has been given in
pregnancy for many years, and influenza and
pertussis vaccines, which are now being recom-
mended for use in pregnancy in some countries.
Maternal tetanus vaccination has been successful in
reducing the burden of neonatal tetanus deaths from
787 000 in 1988 to an estimated 59 000 in 2008.4 This
has set the precedent for future vaccine strategies and
has proven the concept that maternal vaccines can be
effectively delivered in low income countries.
However, maternal vaccination could be used more
widely to reduce the large global health problem of
neonatal death.
Potential disadvantages
An important issue with maternal vaccination relates
to potential inhibitory effects on an infant’s future
response to vaccination. This has been observed with
some vaccines including those for measles, tetanus
and diphtheria and has shaped the current EPI
schedule to some degree. The level of inhibition of
the infant response varies depending on the vaccine in
question and time intervals between different vaccine
doses, with some preventing any antibody response,
some causing only a slight reduction with antibody
titres remaining above a protective threshold, and
others showing no noticeable inhibition.
Other major considerations and concerns, and also
myths, regarding maternal vaccines relate to the
safety for the foetus. Live attenuated vaccines are
contraindicated for use in pregnancy because of the
theoretical risk to the foetus. However, there has been
no established link between vaccines in pregnancy
and serious adverse events.
Which other vaccines might be useful?
In addition to tetanus, the influenza vaccine is
recommended for use in pregnancy by the World
Health Organization in order to protect against the
high levels of morbidity and mortality in young
children and pregnant women seen in the context of
flu epidemics. Current uptake of these recommenda-
tions has, however, been poor and indicates the
existence of barriers to the use of maternal vaccina-
tion in the future, which need to be further explored
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to make maternal immunisation strategies more
widely acceptable.
Another likely candidate for maternal immunisation
that could reduce the burden of neonatal mortality is
the pertussis vaccine. This preventable infection is
responsible for a large number of infant deaths, the
majority of which occur in the first fewmonths of life, a
period before the current vaccination schedule offers
adequate protection. It has yet to be shown whether
maternal pertussis vaccination could reduce infant
infection and mortality, however a strong suggestion of
benefit can be inferred from existing data.5 Following a
significant rise in national cases of pertussis in recent
years and review of safety data, the Centers for Disease
Control in the USA now recommend the use of the
pertussis vaccine in pregnancy.
Vaccination against group B streptococcus would
represent a further opportunity. Currently, this
serious infection in neonates can only be partially
prevented by intra-partum prophylactic antibiotics,
which do not protect against all forms of the disease
and divergent recommendations exist for their use
and screening of pregnant women in different
countries. There is currently no licensed vaccine
against group B streptococcus but vaccines are being
developed actively with the aim of giving these to
pregnant women in the future.
What are the obstacles?
Implementation of maternal vaccination has been
particularly poor in resource-rich countries. For
example, although recommended officially, the uptake
of maternal influenza vaccination in the UK was only
38% in 2010.6 Reasons for this poor uptake are multi-
factorial and include lack of encouragement by health
care workers, refusal by mothers and some practical
barriers. Multiple studies have shown that healthcare
workers often have incorrect knowledge regarding
maternal immunisation and do not offer the vaccines.
Reasons frequently given by mothers for refusing a
maternal vaccine are safety concerns or that they do
not feel that the vaccine is necessary. Poor uptake of
current recommendations is a serious concern for the
successful implementation of future maternal vaccine
programmes and research into understanding and
overcoming the perceived obstacles will be important.
Detailed site-specific and cultural assessments are
needed to fully appreciate the feasibility of, and
barriers to, implementation of maternal vaccination
programmes, particularly in low and middle income
countries (LMIC) where this intervention is likely to
have the greatest effect.
However, the delivery systems are largely in place,
with the majority of pregnant women attending at
least one antenatal clinic in 24 of 28 African countries
surveyed.7 There are a number of characteristics
which suggest that maternal immunisation is suitable
for LMICs, such as the high proportion of mothers
who breast feed and the proven acceptability of
maternal vaccines among women, according to
current maternal and neonatal tetanus programmes.7
Other barriers to implementation in many of these
countries including limited funding and the high
prevalence of HIV and malaria which both limit the
effectiveness of maternal immunisation.
Conclusion
Maternal vaccination can protect the young infant
against vaccine-preventable infections in the first
months of life. This strategy is already widely
implemented with tetanus and influenza vaccines
and many other vaccines could be used in the future,
particularly those for pertussis and group B strepto-
coccus. However, the gap between recommendation
and implementation will have to be successfully
bridged if maternal vaccination is to reach its full
impact and prevent neonatal deaths.
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